|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hottinger AF, Stupp R and Homicsko K:
Standards of care and novel approaches in the management of
glioblastoma multiforme. Chin J Cancer. 33:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goffart N, Kroonen J and Rogister B:
Glioblastoma-initiating cells: Relationship with neural stem cells
and the micro-environment. Cancers (Basel). 5:1049–1071. 2013.
View Article : Google Scholar
|
|
4
|
Pointer KB, Clark PA, Zorniak M, Alrfaei
BM and Kuo JS: Glioblastoma cancer stem cells: Biomarker and
therapeutic advances. Neurochem Int. 71:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramirez YP, Weatherbee JL, Wheelhouse RT
and Ross AH: Glioblastoma Multiforme therapy and mechanisms of
resistance. Pharmaceuticals (Basel). 6:1475–1506. 2013. View Article : Google Scholar
|
|
6
|
Bryukhovetskyi IS, Bryukhovetskyi AS,
Kumeiko VV, Mishenko PV and Khotimchenko YS: Stem cells in
carcinogenesis of glioblastoma multiforme. Genes Cells. 8:13–19.
2013.In Russian.
|
|
7
|
Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang
X, Zhang W, Jin H, Su J, Jiang T, et al: Long-term exposure to
imatinib reduced cancer stem cell ability through induction of cell
differentiation via activation of MAPK signaling in glioblastoma
cells. Mol Cell Biochem. 370:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mendiburu-Eliçabe M, Gil-Ranedo J and
Izquierdo M: Efficacy of rapamycin against glioblastoma cancer stem
cells. Clin Transl Oncol. 16:495–502. 2014. View Article : Google Scholar
|
|
9
|
Eimer S, Dugay F, Airiau K, Avril T,
Quillien V, Belaud-Rotureau MA and Belloc F: Cyclopamine cooperates
with EGFR inhibition to deplete stem-like cancer cells in
glioblastoma-derived spheroid cultures. Neurooncol. 14:1441–1451.
2012.
|
|
10
|
Parney IF and Chang SM: Current
chemotherapy for glioblastoma. Cancer J. 9:149–156. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tamura K, Aoyagi M, Ando N, Ogishima T,
Wakimoto H, Yamamoto M and Ohno K: Expansion of CD133-positive
glioma cells in recurrent de novo glioblastomas after radiotherapy
and chemotherapy. J Neurosurg. 119:1145–1155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brower V: Early-stage progress on glioma
vaccines. J Natl Cancer Inst. 103:1361–1362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rovere RK: Bevacizumab as secondline
treatment of glioblastoma - worth the effort? Klin Onkol.
27:219–220. 2014.
|
|
14
|
Nagasawa T: CXC chemokine ligand 12
(CXCL12) and its receptor CXCR4. J Mol Med (Berl). 92:433–439.
2014. View Article : Google Scholar
|
|
15
|
Bryukhovetskyi IS, Bryukhovetskyi AS,
Mischenco PV and Khotimchenko YS: The role of systemic migration
and homing mechanisms of stem cells in the development of malignant
tumors of the central nervous system and the development of new
cancer therapies. Russian Biotherapeutic J. 4:3–12. 2013.In
Russian.
|
|
16
|
Rispoli R, Conti C, Celli P, Caroli E and
Carletti S: Neural stem cells and glioblastoma. Neuroradiol J.
27:169–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paltsev MA, Ivanov AA and Severin SE:
Intercellular interactions. Medicine (Moscow). 2003, In
Russian.
|
|
18
|
Bryukhovetskiy AS, Shevchenko VE,
Chekhonin VP, Bryukhovetskiy IS, Kovalev SV, Baklaushev VP and
Davydov MI: Comparative proteome mapping of tumor stem cells
isolated from U87 glioblastoma, neural stem and multi-potent
mesenchymal stromal cells of human: From cataloguing of cell
proteins to novel paradigm of proteome-based cell therapy of
tumors. Genes Cells. 8:85–92. 2013.
|
|
19
|
Grobben B, De Deyn PP and Slegers H: Rat
C6 glioma as experimental model system for the study of
glioblastoma growth and invasion. Cell Tissue Res. 310:257–270.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swanson LW: Brain Maps: Structure of the
Rat Brain. 2nd edition. Elsevier; Amsterdam: 1998
|
|
21
|
Pittenger MF: Mesenchymal stem cells from
adult bone marrow. Methods Mol Biol. 449:27–44. 2008.PubMed/NCBI
|
|
22
|
Shen W, Hu JA and Zheng JS: Mechanism of
temozolomide-induced antitumour effects on glioma cells. J Int Med
Res. 42:164–172. 2014. View Article : Google Scholar
|
|
23
|
Tupper DE and Wallace RB: Utility of the
neurological examination in rats. Acta Neurobiol Exp (Wars).
40:999–1003. 1980.
|
|
24
|
Victorov IV, Prass K and Dirnagl U:
Improved selective, simple, and contrast staining of acidophilic
neurons with vanadium acid fuchsin. Brain Res Brain Res Protoc.
5:135–139. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen G, Shen F, Shi Z, Liu W, Hu W, Zheng
X, Wen L and Yang X: Identification of cancer stem-like cells in
the C6 glioma cell line and the limitation of current
identification methods. In Vitro Cell Dev Biol Anim. 44:280–289.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barth RF and Kaur B: Rat brain tumor
models in experimental neurooncology: The C6, 9L, T9, RG2, F98,
BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 94:299–312. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirst TC, Vesterinen HM, Sena ES, Egan KJ,
Macleod MR and Whittle IR: Systematic review and meta-analysis of
temozolomide in animal models of glioma: Was clinical efficacy
predicted? Br J Cancer. 108:64–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Steinbach JP, Wolburg H, Klumpp A, Probst
H and Weller M: Hypoxia-induced cell death in human malignant
glioma cells: Energy deprivation promotes decoupling of
mitochondrial cytochrome c release from caspase processing and
necrotic cell death. Cell Death Differ. 10:823–832. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypocia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang MH, Hu YD, Xu Y, Xiao Y, Luo Y, Song
AC and Zhou J: Human mesenchymal stem cells enhance autophagy of
lung carcinoma cells against apoptosis during serum deprivation.
Int J Oncol. 42:1390–1398. 2013.PubMed/NCBI
|
|
31
|
Hou L, Wang X, Zhou Y, Ma H, Wang Z, He J,
Hu H, Guan W and Ma Y: Inhibitory effect and mechanism of
mesenchymal stem cells on liver cancer cells. Tumour Biol.
35:1239–1250. 2014. View Article : Google Scholar
|
|
32
|
Li Q, Wijesekera O, Salas SJ, Wang JY, Zhu
M, Aprhys C, Chaichana KL, Chesler DA, Zhang H, Smith CL, et al:
Mesenchymal stem cells from human fat engineered to secrete BMP4
are nononcogenic, suppress brain cancer, and prolong survival. Clin
Cancer Res. 20:2375–2387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baraniak PR and McDevitt TC: Stem cell
paracrine actions and tissue regeneration. Regen Med. 5:121–143.
2010. View Article : Google Scholar :
|
|
34
|
Bryukhovetskiy A, Bryukhovetskiy I,
Chekhonin V and Baklaushev V: Experimental cytoregulatory therapy
of brain glial tumors with cell system of hematopoietic precursors
epigenetically reprogrammed of apoptosis induction: Victory in
vitro and failure in vivo. J Neurol. 257(Suppl 1): S152–S153.
2010.
|
|
35
|
Liu J, Zhang Y, Bai L, Cui X and Zhu J:
Rat bone marrow mesenchymal stem cells undergo malignant
transformation via indirect co-cultured with tumour cells. Cell
Biochem Funct. 30:650–656. 2012. View
Article : Google Scholar : PubMed/NCBI
|
